In children, the diagnostic 7-biomarker proteomics panel consisting of ALDOA, C3, LPA, PFN1, PYGB, TLN1, and THBS1 can identify HCM from controls with high sensitivity and specificity, while the 4-biomarker prognostic panel consisting of APOL1, C5b, IGHE, and SAA4 identifies children at high risk of SCD, predicting mortality and adverse arrhythmic outcomes. This evidence concerns the gene PFN1 and Schnyder corneal dystrophy.